South Korea is ramping up cooperation with major countries as it shapes a regulatory science approach to providing services that meet the rapid development pace of cutting-edge technologies, match international standards and improve patient access, amid intensifying global competition to secure novel therapies and modalities.
New Law Aims To Promote, Shape Regulatory Science In Korea
Multi-Faceted Plans In Works
Along with the passage of new regulatory science innovation legislation, South Korea is pursuing a broad range of initiatives to improve and shape its activities in the field to better keep abreast of rapidly advancing biopharma technologies.
More from South Korea
• By
In an ongoing effort to accelerate the commercialization of select innovative drugs and medical devices, Korea’s MFDS is launching a new program for certain products that will receive regular regulatory consultations until they reach the approval stage.
• By
The Pink Sheet looks at what major policies and regulations South Korean authorities prioritized in 2024 and what may be in store for this year.
• By
Speedier approval of clinical trials, flexibility towards new technologies, faster access to new drugs and lingering regulatory barriers to decentralized trials are among the challenges South Korea is facing in becoming a global trial hot spot.
• By
A short-lived but shocking attempt to declare martial law by South Korea's president has thrown the country into political turmoil which could disrupt foreign biopharma investment and key policy initiatives.